Douglas Harrington, MD keynote speaker at recent American Academy of Private Physicians Summit in Washington, D.C.

Harrington spoke about the PULs Cardiac Test developed under his lead by a multi-institutional team, an innovative technology that identifies vulnerable patients missed by conventional methods The blood test, which detects silent cardiac disease and assesses a person’s risk of suffering from a future cardiac event, was featured in U.S. and Canadian media recently The heart assessment test was developed to identify at-risk patients who are not showing outward symptoms, and who would benefit from early intervention
(PR NewsChannel) / October 16, 2015 / WASHINGTON D.C. 

GDBDouglas Harrington, M.D., the innovator of the PULs Cardiac Test, recently took center stage as the keynote speaker at the American Academy of Private Physicians (AAPP) Summit in Washington, D.C.

At the event, Harrington discussed the clinical application of the PULs Cardiac Test to difficult situations as a tool for compliance and disease prevention.

“Cholesterol studies are critical to identifying a patient’s risk of developing heart disease but they do not indicate whether disease is actually present,” says Douglas Harrington, MD, CEO of GD Biosciences, developer of the Cardiac PULs Test. The PULs Cardiac Test provides a missing piece of the heart disease puzzle by enabling physicians to identify silent underlying heart disease without significant clinical symptoms, and in the face of normal cholesterol blood levels.”

The PULs Cardiac Test, an innovative technology that identifies patients at risk of heart attacks who would otherwise be missed by conventional testing methods, is a simple blood test that assesses a person’s risk of suffering from a future cardiac event.

The test can detect evidence of heart disease in asymptomatic individuals and predict their risk of a future coronary event.

“This test is a critical step forward in combatting the world’s deadliest killer,” said Harrington. “The ability to identify underlying silent cardiac disease and predict the likelihood of a cardiac event before it happens is crucial in preserving the health of a patient, especially those who are not showing any symptoms.”

According to Harrington, other tests, including those measuring cholesterol levels, are insufficient to identify individuals who may be facing issues with cardiac health. Multiple studies have shown that roughly 50 percent of heart attack victims had normal cholesterol levels. In fact, most people don’t realize they have problem until they experience either a heart attack or sudden death.

PULs, an acronym for Protein Unstable Lesion Signature, analyzes the proteins secreted from active lesions in the coronary arteries. Measured with other factors including age, race and gender, as well as in conjunction with current testing practices, the heart disease assessment test is able to identify underlying silent cardiac disease activity and predict the likelihood of a future cardiac event within a five year window.

Featured coast-to-coast in the U.S., including television segments in Los Angeles, Austin, Texas, Minneapolis, Minn. and Philadelphia, news of the groundbreaking technology has also reached multiple provinces in Canada, with appearances in The Province, Saskatoon StarPhoenix and Times Colonist.

For more information, take a look at the PULs Cardiac Test’s recent news stories:

Times Colonist – Blood test can assess heart attack risk, conference told

Saskatoon Star Phoenix – New test for heart attack risk

The Province – Blood test can assess heart attack risk, Vancouver conference hears

My Fox Philly – Technology helps predict heart attacks

KTTV – LA – Technology helps predict heart attacks

Fox 9 – Technology helps predict heart attacks

Good Day Austin – Technology helps predict heart attacks

About Douglas Harrington, MD
Dr. Douglas Harrington has over 30 years of experience in the research, development, commercialization, and expansion of innovative healthcare technology and services. As former President and Lab Director of Nichols Institute, Dr. Harrington expanded their molecular genetics, infectious disease, immunology, cytogenetic, and anatomic pathology offerings.

Dr. Harrington holds a number of patents including automated image analysis of residual cancer protein, catalytic heavy metal extraction, and biomarker assays for diagnosis and classification of cardiac disease. He has been involved as director or founder of multiple startup companies – from devices to molecular genetics focusing on immunology, cancer and cardiology, where he has taken a number of new molecular technologies through state and federal regulatory approval.

In addition to being the CEO & Lab Director of Global Discovery Biosciences (GD Biosciences), Dr. Harrington is a Clinical Professor of Pathology at the USC Keck School of Medicine, a published author of numerous peer-reviewed papers, and a sought after speaker in the area of preventive medicine.

About GD Biosciences
Global Discovery Biosciences is a pioneer in the field of diagnostic medicine. The company works on the cutting edge of medical research, turns discoveries into innovative products and brings those products to the global marketplace.

The company works with advanced research teams to develop, manufacture and distribute innovative technology platforms to address the needs of the global disease burden. Its CLIA-certified and GMP laboratory performs a menu of clinically effective tests targeting key health issues. Our goal is to equip physicians with the tools they need to transform health care – one patient at a time.

Media Contact
Adam Farragut
The Publicity Agency
888.399.5534 x7778


Direct link:

SOURCE:  GD Biosciences

This press release is distributed by PR NewsChannel. Your News. Everywhere.